Company intelligence / Profile preview
Pasithea Therapeutics
Miami Beach, Florida, United Statesir.pasithea.com ↗
- Ownership
- Public · KTTA
- Employees
- ~4
- Development stage
- Phase 1
01
Overview
The company’s lead candidate PAS-004, a next-generation macrocyclic MEK inhibitor, has demonstrated a favorable safety profile in an ongoing multi-center Phase 1 trial for advanced cancers and NF1. No dose-limiting toxicities or rash have been observed up to the current highest tested dose. Interim data show clinical activity, target engagement, and tolerability that may differentiate it from existing MEKi therapies[5][7][10].
Additional programs targeting ALS and schizophrenia are in earlier stages of development[2].
The company recently expanded its Phase 1 trial sites to Eastern Europe as well as the US[6].
A recent FDA approval was reported as a key catalyst for stock movement; details suggest regulatory progress but specifics on indication were not provided in search results[6].
Updated interim data will be presented at ASCO June 2025[10].
- Therapeutic areas
- PsychiatryOncologyRare DiseasesNeurology
- Modalities
- Small molecules (macrocyclic MEK inhibitor)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $19M
- Total revenue
- $0
- Enterprise value
- $-45.6B
Beyond the preview
Go deeper on Pasithea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pasithea Therapeutics.